Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
MD-712 (inhaled powder formulation)TYVASO DPI®Treprost® injectionTreprost® inhalation solution
Applicable field (uses covered by this announcement)
Pulmonary arterial hypertensionPulmonary hypertension associated with interstitial lung disease
Launch dateLaunch date in Japan: Not disclosed. In the United States, it has been marketed as TYVASO DPI® since 2022.
Relationship between the counterparty and the company
Mochida Pharmaceutical Co.,Ltd.4534
Relationship with the Company
Under an agreement with United Therapeutics Corporation, 持田製薬 markets treprostinil formulations in Japan.
CounterpartyUnited Therapeutics Corporation
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | MD-712 (inhaled powder formulation), TYVASO DPI®, Treprost® injection, Treprost® inhalation solution |
| Counterparty | United Therapeutics Corporation |
| Relationship with the Company | Under an agreement with United Therapeutics Corporation, 持田製薬 markets treprostinil formulations in Japan. |
| Launch date | Launch date in Japan: Not disclosed. In the United States, it has been marketed as TYVASO DPI® since 2022. |
| Applicable area | Pulmonary arterial hypertension, Pulmonary hypertension associated with interstitial lung disease |
Items this document does not state (13)
Counterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To further expand treatment options for pulmonary hypertension and contribute to improving patients' quality of life.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.